As shown in Fig. 3A, the established orthotopic lung cancer models were randomly divided into four groups (n = 6) and further respectively received treatment with PBS (control group), LLCvac vaccination (subcutaneous injection), anti-PD-1 antibody (intravenous caudal injection) and Bev (intraperitoneal injection), and combined treatment strategy (LLCvac + anti-PD-1 + Bev). This evidence concerns the gene PDCD1 and lung cancer.